Clin2
NCT04557449Possibly a fitRecruiting

Study of an experimental drug for advanced solid tumors

LiposarcomaProstate CancerAdvanced Breast CancerNSCLC (Non-small Cell Lung Cancer)Colorectal Cancer

Treatments studied

PF-07220060LetrozoleFulvestrantMidazolamEnzalutamideGiredestrantTamoxifen

Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin clinical trials.

This trial tests a new drug (PF-07220060) for people with advanced solid tumors, including certain types of breast, lung, prostate, and colorectal cancers. The drug may help slow tumor growth, and researchers are checking its safety and effectiveness.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
430 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have an advanced solid tumor that has not responded to standard treatments.
  • You are generally able to care for yourself (ECOG performance status 0 or 1).
  • Your kidney, liver, and blood cell levels are adequate.
  • You have not had certain other cancers recently (except for treated skin cancers).
  • You have not had major surgery or radiation within the last 4 weeks.
  • You are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Hear when a new Liposarcoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.